Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 4:27 pm Unchanged | 2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | Perceptive Advisors LLC | 2,606,679 7.200% | 0 (Unchanged) | Filing History |
| 2024-02-14 4:21 pm Unchanged | 2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | Baker Bros. Advisors LP | 0 0.000% | 0 (Unchanged) | Filing History |
| 2024-02-14 4:05 pm Purchase | 2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | Commodore Capital LP | 1,934,084 5.400% | 100,000 (+5.45%) | Filing History |
| 2024-02-14 3:51 pm Purchase | 2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | Logos Global Management LP | 150,000 0.400% | 150,000 (New Position) | Filing History |
| 2024-02-14 2:07 pm Unchanged | 2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | Rock Springs Capital Management LP | 0 0.000% | 0 (Unchanged) | Filing History |
| 2024-02-14 09:08 am Purchase | 2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | Avoro Capital Advisors LLC | 2,125,597 5.900% | 2,125,597 (New Position) | Filing History |
| 2024-02-14 08:56 am Purchase | 2023-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | Deep Track Capital, LP | 2,184,440 6.030% | 1,894,118 (+652.42%) | Filing History |
| 2024-02-14 07:02 am Purchase | 2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | RTW Investments, LP | 2,232,760 6.200% | 2,232,760 (New Position) | Filing History |
| 2024-02-13 6:46 pm Unchanged | 2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | BCLS II Equity Opportunities LP | 0 0.000% | 0 (Unchanged) | Filing History |
| 2024-02-13 5:28 pm Purchase | 2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | SUVRETTA CAPITAL MANAGEMENT LLC | 412,395 1.000% | 412,395 (New Position) | Filing History |
| 2024-02-13 4:48 pm Purchase | 2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | Affinity Healthcare Fund, LP | 653,409 1.810% | 653,409 (New Position) | Filing History |
| 2024-02-13 09:39 am Purchase | 2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | Polar Capital Holdings Plc | 500,000 1.050% | 500,000 (New Position) | Filing History |
| 2024-02-12 12:03 pm Purchase | 2024-02-09 | 13G | Spyre Therapeutics, Inc. SYRE | FMR LLC | 6,206,451 13.065% | 2,420,574 (+63.94%) | Filing History |
| 2024-02-09 10:20 am Purchase | 2024-02-08 | 13G | Spyre Therapeutics, Inc. SYRE | FMR LLC | 3,785,877 7.969% | 3,785,877 (New Position) | Filing History |
| 2024-02-08 4:36 pm Purchase | 2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | Integrated Core Strategies (US) LLC | 108,486 0.300% | 108,486 (New Position) | Filing History |
| 2023-12-29 5:00 pm Sale | 2023-12-29 | 13D | Spyre Therapeutics, Inc. SYRE | Fairmount Funds Management LLC | 836,459 2.320% | -2,977,442 (-78.07%) | Filing History |
| 2023-12-13 3:50 pm Purchase | 2023-11-24 | 13G | Spyre Therapeutics, Inc. SYRE | Perceptive Advisors LLC | 2,606,679 7.200% | 2,606,679 (New Position) | Filing History |
| 2023-12-11 5:21 pm Unchanged | 2023-12-07 | 13D | Spyre Therapeutics, Inc. SYRE | Fairmount Funds Management LLC | 3,813,901 10.590% | 0 (Unchanged) | Filing History |
| 2023-12-01 4:15 pm Purchase | 2023-11-24 | 13G | Spyre Therapeutics, Inc. SYRE | Commodore Capital LP | 1,834,084 6.100% | 1,834,084 (New Position) | Filing History |
| 2023-11-29 5:08 pm Purchase | 2023-11-24 | 13D | Spyre Therapeutics, Inc. SYRE | Fairmount Funds Management LLC | 3,813,901 12.700% | 3,813,901 (New Position) | Filing History |